NCT05737069View on ClinicalTrials.gov

A Bioequivalence Study of Two Ibuprofen Arginine Granules 400 mg Formulations Under Fasting and Fed Conditions in Chinese Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

May 15, 2023

Study Completion Date

May 15, 2023

Conditions
Pain
Interventions
DRUG

Ibuprofen arginine granules 400 mg

Experimental- Ibuprofen arginine granules 400 mg, one sachet administration containing 400 mg ibuprofen granules.

DRUG

Ibuprofen arginine granules 400 mg (Spedifen)

Marketed drug- Ibuprofen arginine granules 400 mg (Spedifen), one sachet administration containing 400 mg ibuprofen granules.

Trial Locations (1)

611130

Clinical Pharmacological Research Center, Wenjiang

All Listed Sponsors
lead

HALEON

INDUSTRY